BIVI Research Note — Binary Catalysts Demand Patience
BioVie faces two near-term clinical catalysts, but prior trial failure, liquidity, and financing risk favor patience.
BIVI
BIVI Deep Coverage Review — Two Clinical Readouts, One Narrowing Runway
BioVie’s two near-term Phase 2 readouts confront a prior late-stage failure, financing dependence, thin liquidity, and an unusually fragile tape.